Mo4Zol2Mn

Mo4Zol2Mn is a heterometallic coordination complex composed of molybdenum (Mo), manganese (Mn), and the bisphosphonate zoledronic acid (Zol). It is a preclinical research compound investigated for its anti-tumor properties, particularly in the treatment of breast cancer (DOID_1612). The complex is designed to leverage the pharmacological activity of zoledronic acid—a potent inhibitor of farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway—while potentially enhancing its efficacy through the synergistic biological effects of the molybdenum and manganese metal centers. Preclinical studies have demonstrated that Mo4Zol2Mn exhibits significant cytotoxicity against breast cancer cell lines, such as MCF-7, by inducing apoptosis and inhibiting cell proliferation and migration. This coordination complex represents an effort to develop multi-targeted metallodrugs that can address both primary tumor growth and associated bone complications in cancer patients.

Other names

molybdenum-manganese-zoledronate complex[Mo4O12(Zol)2Mn(H2O)4]·2H2OMo4Zol2Mn2Mo-4Zol2Mn2Mo 4Zol2Mn2[Mo4O12(Zol)2Mn2(H2O)8]·4H2O